Utilising a cell’s own molecular delivery system could enable specific biomedical treatments In the world of drug delivery, getting an active compound to the right tissue or organ before the body’s defences break it down can make the difference between wellbeing and sickness, life and death. Clever capsules and coatings can boost the drug effect
Results from three long-term studies following host and microbiome characteristics during pregnancy and preterm birth, inflammatory bowel disease, and prediabetes have expanded our understanding of how humans and microbes interact and the resulting consequences for our health. The studies were funded as part of a second phase of the National Institutes of Health’s Human Microbiome Project (HMP).
The wearable neurotechnology market targets consumers with promises of cognitive benefit and personal wellness. Scientific evidence is essential to substantiate claims about utility, safety, and efficacy and for informed choice and public trust. nhance your memory. Boost your mood. Lose weight more easily. Learn golf, CrossFit, or the clarinet faster. Or even: Regain more independence,
A new report, with contributions from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health, provides a roadmap for translational research on artificial intelligence (AI) in medical imaging. The report, published in the May 28, 2019, Journal of the American College of Radiology, identifies research priorities that leverage
Walking as few as 4400 steps per day may decrease the risk for all-cause mortality among older women, according to a study published online today in JAMA Internal Medicine and presented simultaneously at the American College of Sports Medicine (ACSM) 2019 Annual Meeting. The risk for death fell with increasing number of steps per day, and these benefits leveled
The UK ATTC Network is a world-first system of Advanced Therapy Treatment Centres (ATTCs), operating within the NHS framework and coordinated by CGT Catapult, that is addressing the unique and complex challenges of bringing pioneering advanced therapies to patients. The project has been funded by the Industrial Strategy Challenge Fund, part of the government’s modern Industrial Strategy,
Cancer drugs are being approved by the FDA at an alarmingly fast rate after preliminary studies show encouraging results. However, after more careful follow-up trials were done, most of these drugs did not show any clear benefits. Cancer drugs are usually granted accelerated approval in the hopes of providing patients faster access to medicine that
Dr. Robert A. Preti, theCEO and President of Hitachi Chemical Advanced Therapeutics Solutions (HCATS), was recently interviewed by Global Business Reports (GBR) for their 2019 US Biopharmaceuticals report. The GBR report covers a range of topics, such as the state of the biopharma industry, new developments in biopharmaceutical manufacturing, the investment climate for cell and gene
A decade ago researchers announced development of a cancer immunotherapy called CAR (for chimeric antigen receptor)-T, in which a patient is re-infused with their own genetically modified T cells equipped to mount a potent anti-tumour attack. Since then CAR T approaches (one of several strategies collectively known as “adoptive T cell transfer”) have made headlines
Athersys announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the data from the clinical trial, referred to as the MUST-ARDS trial, during his presentation today at the American Thoracic Society International Conference in Dallas, Texas, the
